PT  - JOURNAL ARTICLE
AU  - Caleb Weihao Huang
AU  - Poh Hui Wee
AU  - Lian Leng Low
AU  - Ying Leng Agnes Koong
AU  - Htay Htay
AU  - Qiao Fan
AU  - Wai Yin Marjorie Foo
AU  - Jun Jie Benjamin Seng
TI  - Prevalence and risk factors associated with Anxiety Symptoms and Disorders Among Chronic Kidney Disease patients – A Systematic Review and Meta-analysis of studies
AID  - 10.1101/2020.06.03.20121798
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.03.20121798
4099  - http://medrxiv.org/content/early/2020/06/05/2020.06.03.20121798.short
4100  - http://medrxiv.org/content/early/2020/06/05/2020.06.03.20121798.full
AB  - Background Anxiety is associated with poor health outcomes among chronic kidney disease (CKD) patients. This review summarizes the prevalence and risk factors associated with anxiety symptoms and disorders among CKD patients.Methods Articles evaluating the prevalence and risk factors associated with anxiety symptoms and disorders among CKD patients, as diagnosed via DSM 4th or 5th edition criteria, clinical interviews or validated questionnaires, were searched in Medline®, Embase®, PsychINFO® and CINAHL®. Using random-effects meta-analyses, prevalence of anxiety was estimated. A narrative review on the risk factors associated with anxiety was presented.Results From 4941 articles, 61 studies were included. Pooled prevalence of anxiety disorders (9 studies, n=1071) among CKD patients across studies was 18.9% while that of anxiety symptoms (52 studies, n=10,739) was 42.8%. Across continents, prevalence of anxiety symptoms was highest in Europe and Asia. Between pre-dialysis and dialysis patients, prevalence of anxiety symptoms was statistically comparable at 30.5% and 42.1% respectively. Most commonly studied risk factors associated with anxiety were female gender, increased age, concomitant depression, and increased comorbidities.Conclusion Given the high prevalence of anxiety disorders and symptoms, there is a need for developing clinical guidelines on anxiety screening among CKD patients, facilitating early identification of at-risk patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is presented in the paper and the accompanying supplementary data files.